Table 3.
Measures of Impairment and Perception
| DMD | BMD | LGMD | FSHD | CTRL | |
|---|---|---|---|---|---|
| KEMVC (N.m) | 12.6 ± 8.8 B***,LG***,F***,C*** | 96.6 ± 60.0 C** | 98.2 ± 56.4 C* | 123.6 ± 78.2 | 164.6 ± 55.9 |
| CIS Severity | 34.4 ± 8.7 F*,C*** | 33.2 ± 10.5 F**,C*** | 34.4 ± 10.9 C*** | 43.0 ± 5.3 C*** | 14.1 ± 6.1 |
| VAS Pain | 2.5 ± 1.6 C** | 3.5 ± 2.5 C*** | 3.6 ± 2.8 C*** | 3.9 ± 2.2 C*** | 0.4 ± 0.7 |
| NEADL | 13.9 ± 6.0 B***,LG*,F***,C*** | 36.7 ± 14.4C*** | 29.3 ± 7.1 C*** | 39.4 ± 14.6C** | 63.6 ± 3.1 |
| Self-Efficacy | 31.0 ± 6.2 | 28.3 ± 5.9 | 31.0 ± 5.1 | 30.7 ± 7.5 | 34.3 ± 4.3 |
Measures of Impairment and Perception
DMD Duchenne Muscular Dystrophy, BMD Beckers Muscular Dystrophy, LGMD Limb-Girdle Muscular Dystrophy, FSHD Facioscapulohumeral Muscular Dystrophy, CIS Checklist Individual Strength, VAS Visual Analog Scale, KEMVC Knee Extension Maximal Voluntary Contraction, N.m Newton Metres, NEADL Nottingham Extended Activities of Daily Living; B denotes significant difference from BMD; LG denotes significant difference from LGMD; F denotes significant difference from FSHD; C denotes significant difference from CTRL; * denotes significance P < .05; ** denotes significance P < .01; *** denotes P < .001